Eli Lilly And Co vs 3M Company — how do they compare? Eli Lilly And Co trades at $1,223.26 (market cap $1.08T), while 3M Company trades at $183.64 (market cap $94.44B). The key difference: Eli Lilly And Co is far larger — about 11.4× 3M Company's market cap, and 3M Company pays the higher dividend (1.7%). Which is the better fit depends on your goals.
| LLY | MMM | |
|---|---|---|
Market Cap | $1.08T | $94.44B |
Sector | Health | Industrials |
52-Week High | $1.24K | $183.13 |
52-Week Low | $639.43 | $141.10 |
Enterprise Value | $1.13T | $103.67B |
Dividend Yield | 0.57% | 1.7% |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
3M (MMM) trades at $183.58, up 0.85% with strong technical momentum and bullish moving average signals. The company delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.40 exceeding expectations by 6.7%, and raised full-year guidance. Revenue trends show stabilization after 2023 challenges, with 2025 revenue of $24.95B and net income margin of 13.02%. Analyst sentiment is mixed with 48% buy ratings but the stock trades above the consensus price target of $173.
The outlook remains positive with operational improvements and innovation driving growth, particularly in Safety & Industrial and Transportation segments. Key risks include litigation liabilities, macroeconomic headwinds, and valuation concerns with elevated P/E of 32.5. The EBO partnership with Microsoft presents long-term data center growth opportunities, though current pricing may limit near-term upside potential.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →